Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1193 studies found for:    Open Studies | "Antineoplastic Agents, Alkylating"
Show Display Options
Rank Status Study
1 Recruiting Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Conditions: Diffuse, Large B-Cell, Lymphoma;   Follicular Lymphoma, Grade 3b;   Transformed Lymphoma / DLBCL
Interventions: Drug: denintuzumab mafodotin;   Drug: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin;   Drug: vincristine;   Drug: prednisone
2 Recruiting PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis
Conditions: Primary Myelofibrosis;   Myeloproliferative Disorders
Interventions: Procedure: Allogeneic hematopoietic stem cell transplantation;   Drug: Busulfan;   Drug: Fludarabine monophosphate;   Drug: Cyclophosphamide;   Drug: Ruxolitinib
3 Recruiting GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia
Conditions: Leukemia, Acute Lymphoblastic;   Acute Myeloid Leukemia;   Mixed-Lineage Acute Leukemias
Interventions: Procedure: Allogeneic stem cell transplantation;   Drug: Fludarabine monophosphate;   Drug: Busulfan;   Drug: Bendamustine
4 Recruiting Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT
Conditions: Leukemia, Chronic Myeloid;   Myelodysplastic Syndromes;   Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
Interventions: Procedure: Unrelated allogeneic stem cell transplantation;   Drug: Busulfan;   Drug: Fludarabine monophosphate;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Cyclophosphamide;   Drug: Thymoglobulin
5 Recruiting Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors
Condition: Breast Cancer
Interventions: Device: Focused Microwave Thermotherapy;   Drug: Chemotherapy (control)
6 Not yet recruiting Disulfiram in Recurrent Glioblastoma
Conditions: Glioma;   Glioblastoma
Interventions: Drug: Disulfiram;   Dietary Supplement: Copper;   Drug: Alkylating Agents
7 Not yet recruiting A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma
Conditions: Multiple Myeloma;   Non-Hodgkin's Lymphoma
Interventions: Dietary Supplement: Enterade;   Dietary Supplement: Placebo;   Other: Standard Supportive Care
8 Recruiting PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage
Condition: Lymphoma
Interventions: Drug: pegaspargase;   Drug: Gemcitabine;   Drug: Oxaliplatin;   Drug: Dexamethasone;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone;   Radiation: IMRT
9 Not yet recruiting Optimizing Cord Blood and Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)
Condition: Severe Aplastic Anemia
Interventions: Drug: Antithymocyte Globulin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation (TBI);   Procedure: UCB HSCT;   Procedure: Haplo HSCT;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil (MMF);   Drug: G-CSF
10 Not yet recruiting Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Secondary Myelofibrosis
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacological Study;   Drug: Ruxolitinib Phosphate;   Drug: Sirolimus;   Drug: Tacrolimus
11 Not yet recruiting Multi-Dose CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
Conditions: Hodgkin's Lymphoma;   Non-Hodgkin Lymphoma
Interventions: Genetic: CAR T Cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
12 Recruiting Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
Conditions: Leukemia, Lymphoid;   Leukemia, Myeloid;   Myelodysplastic Syndromes;   Myelofibrosis;   Lymphoma, Malignant;   Multiple Myeloma;   Waldenstrom Macroglobulinemia
Interventions: Drug: Fludarabine;   Drug: Busulfan;   Biological: Rabbit ATG;   Drug: Methotrexate
13 Not yet recruiting A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Chlorambucil;   Drug: Obinutuzumab
14 Not yet recruiting Carboplatin-cyclophosphamide Combined With Atezolizumab
Conditions: Breast Cancer;   Cervix Cancer;   Ovarian Cancer;   Endometrial Cancer
Intervention: Drug: carbplatin, cyclophophamide, atezolizumab
15 Not yet recruiting Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
Conditions: Primary Effusion Lymphoma;   B-Cell Lymphoma
Interventions: Drug: Lenalidomide;   Drug: Rituximab;   Drug: Prednisone;   Drug: Etopside;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide on day 10 (for 6 cycles), each patient will get a 750 mg/m2 dose.
16 Recruiting Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Epirubicin 90 mg/m2 iv;   Drug: Cyclophosphamide 600 mg/m2 iv;   Drug: Docetaxel 100 mg/m2 iv OR paclitaxel 80 mg/m2 iv;   Drug: Trastuzumab 8 mg/kg iv saturation, then 6 mg/kg iv (HER2 positive patients only);   Drug: Pertuzumab 840 mg iv saturation, then 420 mg iv (selected HER2 positive patients only);   Dietary Supplement: Tocotrienol 300 mg x 3 daily
17 Recruiting Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.
Conditions: Multiple Myeloma;   Amyloidosis
Interventions: Device: Melphalan;   Drug: Pegfilgrastim;   Procedure: Autologous Hematopoietic Progenitor Cell Transplant
18 Not yet recruiting Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)
Condition: Hepatocellular Carcinoma
Interventions: Genetic: GLYCAR T cells;   Drug: Cytoxan;   Drug: Fludarabine
19 Recruiting Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Doxorubicin Hydrochloride Liposome injection and cyclophosphamide;   Drug: pirarubicin and cyclophosphamide
20 Recruiting Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
Conditions: Glioblastoma;   Malignant Glioma
Interventions: Drug: MRZ;   Drug: TMZ;   Radiation: RT

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years